리가켐바이오

141080KOSDAQ자연과학 및 공학 연구개발업

44.0 / 100

Reference Date: 2026-04-13

Financial Score10.5 / 40

News Sentiment12.5 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Declined 6.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Ligacem Bio is a biopharmaceutical company specializing in next-generation ADC (Antibody-Drug Conjugate) technology through its proprietary platform 'ConjuALL', targeting unmet medical needs in oncology. The company has secured multiple technology transfer agreements with global pharmaceutical firms, including Fosun Pharma and Janssen, and reported revenue of approximately 10.54 billion KRW in 2024. It also operates a medical supply business, contributing to its diversified revenue streams.

Number of Employees

180people

Average Salary

157.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

12.73Industry Average 3.820.0Point

3.3x industry avg (risky)

ROE

-15.82Industry Average -32.113.5Point

Well below industry avg

Debt Ratio

18.41Industry Average 7.520.0Point

2.4x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲140.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼167.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.0% (improving, 3yr)

Detailed News Sentiment

9 totalPositive 0Neutral 4Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position6.0Point

52w upper range (78%)

Current 188,200Won52-week high 213,50052-week low 97,000

1-month return2.0Point

1m -6.37% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

11 totalPositive 0Neutral 11Negative 0

Neutral주식매수선택권행사2026-04-08
Neutral투자판단관련주요경영사항 (신규 기전 신약 연구개발을 위한 기술도입 계약 체결)2026-04-06
Neutral투자판단관련주요경영사항 (신규 항체-약물 결합체(ADC) 연구개발을 위한 공동연구 및 항체 기술도입 계약 해지)2026-04-02
Neutral주식등의대량보유상황보고서(일반)2026-04-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-01